Ann: MSB Q2 Financial Results and Operational Highlights, page-21

First 21 Last

Share
Profile

Follow
stockrock

5,491 Posts.

8962

25/02/22

11:22

Post #: 59819165
Share

Originally posted by aquazul: ↑

Glad to see that Investors are picking up on the NIH being the sponsor for the confirmatory phase 3 trial for Covid 19 ARDS. This is the first time that Silviu has confirmed they are still on board and working with them towards the regulatory approval EUA stage. As I said before this is significant, because NIH funding in my view will only happen if the FDA tips them off that aGVHD approval is a strong likelihood. Very encouraging news and nice that Silviu was confident enough to mention them by name as their partner for Covid ARDS.

The requested CHF data submission for ischemic diabetic population with raised inflammatory biomarkers is very imminent and almost ready to be submitted (from Silviu’s CC comments). Let’s assume FDA cardiovascular team are actually working on the file and just awaiting the dataset (they already have the top line data provided to them last November), then I can see a quick turnaround and probably another CHF/FDA meeting in April. So we MIGHT know the chances of accelerated approval or single trial approval as soon as April. If the NDA gives the nod, the share price would explode as this is a multi-billion blockbuster indication that could see revenues coming as soon as 2023/4. This would be the event that flushes out the skeptical shorters and basically would be an annihilating event for the long term shorters.

Another significant piece of information that Silviu provided is that they ARE partnering up for the planned CLBP trial and more information on this shall be provided to the market shortly.

So expect announcements on partnerships; CHF data submitted; BLA for aGVHD, etc in the next month(s).

One more thing: BLA for aGVHD to be submitted in “short course”. We need to re-listen to what Silviu said as I definitely heard those words. Sounds to be more likely the submission before the end of March (targeted) and then it’s always a month and half for BLA acceptance and PDUFA date would then be 6-months later, which falls within second half which Silviu indicates…
However I don’t think we’ll need to wait more than 2-months for the full approval after NDA is accepted, assuming the Singapore facility can be inspected in this timeframe. Why? The ODAC is done and FDA had already done 90% of the application review beforehand, so really this is going to be much faster this time around (except the company cannot speculate or guide the market on this as they don’t want to get ahead of themselves and say things that could upset their fantastic relationship which they seem to be enjoying currently with the FDA).

One last comment: Nice to see Silviu’s “camaraderie” with Dr. Eric Rose as new CMO which was very apparent in this call.
Dr. Rose also sounded very bullish about MSB’s prospects in the future. With his distinguished career, I can’t see why he would say something he didn’t seriously believe is achievable.

Expand

I must've missed the line where they said they were partnering up for CLBP .. that's a 180 from a few months ago?

Someone must've approached them with a decent offer for them to change direction like that.

MSB Price at posting: $1.08 Sentiment: Buy Disclosure: Held
14 Upvote

0 Great analysis

Reply

Top Stories

LML

Lincoln Minerals to kick off fieldwork at Yallunda uranium project in the nuclear state, SA

TNC

True North shares jump on positive activity report as Cloncurry aims for Q1 production deadline

QGL

Quantum Graphite snags new exploration licence in SA ahead of maiden drilling

MKT

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

WML

Woomera kicks off 2-pronged drilling at Mongolia's Bronze Fox Cu-Au play

There are more pages in this discussion • 199 more messages in this thread...

First 21 Last

Add MSB (ASX) to my watchlist

(20min delay)
Last $1.44		Change -0.010(0.69%)		Mkt cap ! $1.644B

Open	High	Low	Value	Volume
$1.50	$1.50	$1.43	$4.048M	2.778M

Buyers (Bids)

No.	Vol.	Price($)
6	26808	$1.44

Sellers (Offers)

Price($)	Vol.	No.
$1.45	16001	1

View Market Depth

No.	Vol.	Price($)
6	26808	1.440
2	28628	1.435
8	68533	1.430
5	155422	1.425
4	32112	1.420

Price($)	Vol.	No.
1.445	16001	1
1.450	4515	1
1.455	6500	1
1.460	45215	3
1.465	36008	2

Last trade - 16.10pm 14/10/2024 (20 minute delay)

MSB (ASX) Chart

Ann: MSB Q2 Financial Results and Operational Highlights, page-21

Lincoln Minerals to kick off fieldwork at Yallunda uranium project in the nuclear state, SA

True North shares jump on positive activity report as Cloncurry aims for Q1 production deadline

Quantum Graphite snags new exploration licence in SA ahead of maiden drilling

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

Woomera kicks off 2-pronged drilling at Mongolia's Bronze Fox Cu-Au play

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: MSB Q2 Financial Results and Operational Highlights, page-21

Top Stories

Lincoln Minerals to kick off fieldwork at Yallunda uranium project in the nuclear state, SA

True North shares jump on positive activity report as Cloncurry aims for Q1 production deadline

Quantum Graphite snags new exploration licence in SA ahead of maiden drilling

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

Woomera kicks off 2-pronged drilling at Mongolia's Bronze Fox Cu-Au play

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News